Q-omics provides the consensus-scored LINC02474 profile across patient tissues and cancer cell-line models. LINC02474 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC02474 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, LINC02474 RNA expression shows 6,350 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight COAD, and KIRC as cancer lineages where LINC02474 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02474 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02474 survival associations across molecular data types. LINC02474 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02474 RNA expression–survival associations across cancer types. High LINC02474 expression shows unfavorable associations in COAD, THCA, KIRP, KICH and ACC, but favorable associations in UCS. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC02474 RNA expression.
This table summarizes LINC02474 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02474. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02474 shows higher tumor expression in KIRC, LUAD, THCA, COAD, BLCA and STAD. The KIRC box plot shows higher LINC02474 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p < 0.001).
This table shows molecular features associated with LINC02474 in patient tissues and cancer cell lines. In patient samples, LINC02474 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
